QT-RR relationships and suitable QT correction formulas for halothane-anesthetized dogs

Journal of Toxicological Sciences

Volumn 31, Issue 4, 2006, Pages 381-390

  Tabo, Mitsuyasu ^a,b   Nakamura, Mikiko ^a   Kimura, Kazuya ^a   Ito, Shigeo ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Analysis of covariance; Fridericia's formula; Halothane anesthetized dogs; QT correction formula; QT interval prolongation

Indexed keywords

ASTEMIZOLE; HALOTHANE; PROPRANOLOL; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEART ATRIUM PACING; HEART RATE; MALE; NONHUMAN; QT INTERVAL; QT PROLONGATION; RR INTERVAL;

CANIS FAMILIARIS;

EID: 33750905495     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.31.381     Document Type: Article

References (28)

1. Ando, K., Hombo, T., Kanno, A., Ikeda, H., Imaizumi, M., Shimizu, N., Sakamoto, K., Kitani, S., Yamamoto, Y., Hizume, S., Nakai , K. , Kitayama, T. and Yamamoto, K. (2005): QT PRODACT: In vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J. Pharmacol. Sci., 99, 487-500.
2. Bazett, H.C. (1920): An analysis of the time-relations of electrocardiograms. Heart, 7, 353-370.
3. Biliczki, P., Virag, L., Iost, N., Papp, J.G. and Varro, A. (2002): Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br. J. Pharmacol., 137, 361-368.
4. Cavero, I., Mestre, M., Guillon, J.M. and Crumb, W. (2000): Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Exp. Opin. Pharmacother., 1, 947-973.
5. + current in rat ventricular myocytes. Br. J. Pharmacol., 131, 223-230.
6. De Ponti, F., Poluzzi, E. and Montanaro, N. (2001): Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus. Eur. J. Clin. Pharmacol., 57, 185-209.
7. Fridericia, L.S. (1920): Die systolendauer im elektrokardiogramm bei normaln menschen und bei herzkranken. Acta Med. Scand., 53, 469-486.
8. Funck-Brentano, C. (1993): Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. Eur. Heart J., 14, 30-35.
9. Hammond, T.G., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Redfern, W.S., Sullivan, A.T. and Camm, A.J. (2001): Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey. Cardiovasc. Res., 49, 741-750.
10. Hondeghem, L.M. and Snyders, D.J. (1990): Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation, 81, 686-690.
11. Hoppu, K., Tikanoja, T., Tapanainen, P., Remes, M., Saarenpaa-Heikkila, O. and Kouvalainen, K. (1991): Accidental astemizole overdose in young children. Lancet, 338, 538-540.
12. ICH Harmonised Tripartite Guideline, Safety Pharmacology Studies for Human Pharmaceuticals S7A. Recommended for adoption at step 4 of the ICH process on 8 November 2000 by the ICH Steering Committee. ICH; http://www.ich.org/
13. ICH Harmonised Tripartite Guideline, The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals S7B. Recommended for adoption at step 4 of the ICH process on 12 May 2005 by the ICH Steering Committee. ICH; http://www.ich.org/.
14. JIS (1965): The t-test with F-test for homogeneity of variance. Significance test of difference between the two population means (standard deviations unknown, two-sided). Japanese Industry Standard Z9049.
15. Laer, S., Wauer, I. and Scholz, H. (2001): Small blood volumes from children for quantitative sotalol determination using high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl., 753, 421-425.
16. Li, J. and Correa, A.M. (2002): Kinetic modulation of HERG potassium channels by the volatile anesthetic halothane. Anesthesiology, 97, 921-930.
17. Matsunaga, T., Mitsui, T., Harada, T., Inokuma, M., Murano, H. and Shibutani, Y. (1997): QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. J. Pharmacol. Toxicol. Methods, 38, 201-209.
18. Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Palethorpe, S., Siegl, P.K.S., Strang, I., Sullivan, A.T., Wallis, R., Camm, A.J. and Hammond, T.G. (2003): Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res., 58, 32-45.
19. + current in guinea pig ventricular cells. J. Pharmacol. Sci., 95, 363-373.
20. Simons, F.E.R., Kesselman, M.S., Giddins, N.G., Pelech, A.N. and Simons, K.J. (1988): Astemizole-induced torsade de pointes. Lancet, 2, 624.
21. Spence, S., Soper, K., Hoe, C.M. and Coleman, J. (1998): The heart rate-corrected QT interval of conscious beagle dogs: A formula based on analysis of covariance. Toxicol. Sci., 45, 247-258.
22. + current by halothane and isoflurane. Anesth. Analg., 90, 824-833.
23. Kr blockade. Eur. J. Pharmacol., 507, 169-177.
24. Tashibu, H., Miyazaki, H., Aoki, K., Akie, Y. and Yamamoto, K. (2005): QT PRODACT: In vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci., 99, 473-486.
25. Toyoshima, S., Kanno, A., Kitayama, T., Sekiya, K., Nakai, K., Haruna, M., Mino, T., Miyazaki, H., Yano, K. and Yamamoto, K. (2005): QT PRODACT: In vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci., 99, 459-471.
26. Van de Water, A., Verheyen, J., Xhonneux, R. and Reneman, R.S. (1989): An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J. Pharmacol. Methods, 22, 207-217.
27. Welch, B.L. (1938): The significance of the difference between two means when the population variances are unequal. Biometrika, 29, 350-362.
28. Yamamoto, K., Tamura, T., Imai, R. and Yamamoto, M. (2001): Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. Toxicol. Sci., 60, 165-176.